Raymond James & Associates Purchases 7,268 Shares of Invesco Biotechnology & Genome ETF (NYSEARCA:PBE)

Raymond James & Associates boosted its position in Invesco Biotechnology & Genome ETF (NYSEARCA:PBE) by 121.6% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 13,247 shares of the company’s stock after purchasing an additional 7,268 shares during the period. Raymond James & Associates’ holdings in Invesco Biotechnology & Genome ETF were worth $872,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also bought and sold shares of PBE. Creative Financial Designs Inc. ADV increased its stake in Invesco Biotechnology & Genome ETF by 6.6% in the fourth quarter. Creative Financial Designs Inc. ADV now owns 3,347 shares of the company’s stock valued at $220,000 after purchasing an additional 206 shares in the last quarter. Dakota Wealth Management grew its stake in shares of Invesco Biotechnology & Genome ETF by 2.1% in the 3rd quarter. Dakota Wealth Management now owns 12,280 shares of the company’s stock valued at $700,000 after buying an additional 250 shares during the period. Kestra Advisory Services LLC increased its position in Invesco Biotechnology & Genome ETF by 4.2% in the 3rd quarter. Kestra Advisory Services LLC now owns 6,362 shares of the company’s stock valued at $363,000 after buying an additional 254 shares in the last quarter. UBS Group AG raised its stake in Invesco Biotechnology & Genome ETF by 9.6% during the 3rd quarter. UBS Group AG now owns 94,250 shares of the company’s stock worth $5,376,000 after buying an additional 8,266 shares during the period. Finally, Penobscot Investment Management Company Inc. bought a new position in Invesco Biotechnology & Genome ETF in the third quarter worth approximately $562,000.

Invesco Biotechnology & Genome ETF Price Performance

Shares of PBE stock opened at $60.40 on Tuesday. The company has a market cap of $229.53 million, a P/E ratio of 16.61 and a beta of 0.92. Invesco Biotechnology & Genome ETF has a one year low of $52.47 and a one year high of $67.76. The firm has a 50-day moving average of $64.09 and a 200-day moving average of $61.84.

About Invesco Biotechnology & Genome ETF

PowerShares Dynamic Biotechnology & Genome Portfolio (the Fund) is based on the Dynamic Biotechnology & Genome Intellidex Index (the Index). The Fund seeks investment results that correspond generally to the price and yield of the Index. The Index consists of stocks of 30 the United States biotechnology and genome companies.